What are the indications for Erdafitinib?

Erdafitinib (Erdafitinib) is a small molecule targeted therapy drug targeting the fibroblast growth factor receptor (FGFR). Erdafitinib is primarily approved for the treatment of advanced or metastatic urothelial carcinoma (UC).

Urothelial carcinoma is a cancer that occurs in the bladder, urethra, renal pelvis and other parts of the body, and erdafitinib has shown excellent efficacy in the treatment of this specific type of cancer. Specifically, the drug is mainly suitable for patients with advanced urothelial cancer who have FGFR3 or FGFR2 gene abnormalities (including gene overexpression, gene mutations, etc.).

FGFR regulates cell growth and differentiation in normal cells, but in some tumors, especially urothelial cancer, FGFR is often abnormally activated, promoting the growth and spread of cancer cells. Erdafitinib targets this abnormal activation mechanism and precisely inhibits the FGFR signaling pathway, thereby inhibiting the growth of cancer cells.

Importantly, before patients receive erdafitinib treatment, they usually need to undergo genetic testing to determine whether there is an abnormality in theFGFR gene, which helps ensure the rational use of the drug.

It should be noted that the indication information of the drug may be updated at any time, so patients are advised to consult a professional doctor or consult the latest medical literature to obtain accurate and up-to-date information.

Erdafitinib is not currently available in the country, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.